Zobrazeno 1 - 10
of 127
pro vyhledávání: '"John E Janik"'
Autor:
Rebecca Kristeleit, Juan Martin-Liberal, Kristen Spencer, Janice M Mehnert, Maria Vieito, Elizabeth J Davis, Angela Orcurto, Thomas Condamine, Daniel C Cho, Jennifer Pulini, Rowan E Miller, Sarah P Blagden, Dominik Berthold, Dana B Cardin, Prashanth Hari Dass, John E Janik, Jason Clark, Xuejun Chen
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to pro
Externí odkaz:
https://doaj.org/article/ac1ed19fc2ac410aa1aabfc845b35fef
Autor:
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, N
Externí odkaz:
https://doaj.org/article/fa3f41ad888d41f5a1c759f8b6fa21b2
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Effects of the combination therapy of anti-OX40 and anti-PD-1 Abs with tumor vaccine on spleen and tumor T-cell infiltration and clonality.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44c63ff14df19403c3f2a7fca5a301e1
https://doi.org/10.1158/2326-6066.22539581
https://doi.org/10.1158/2326-6066.22539581
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the clinic to achieve improved antitumor effects. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c0801e54b2055f9ba4cd12f3c386703
https://doi.org/10.1158/2326-6066.c.6549134.v1
https://doi.org/10.1158/2326-6066.c.6549134.v1
Autor:
Samir N. Khleif, Seema Gupta, Mikayel Mkrtichyan, John E. Janik, Scott A. Hammond, Harlan Robins, Catherine Sanders, Erik Yusko, Rachel M. Gittelman, Pankaj Gaur, Sudha Ananth, Peng Zeng, Vivek Verma, Shamim Ahmad, Rajeev K. Shrimali
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::615d975cb0e07c871f0a46f68a354f77
https://doi.org/10.1158/2326-6066.22539587
https://doi.org/10.1158/2326-6066.22539587
Autor:
John C. Morris, Thomas A. Waldmann, Seth M. Steinberg, Cathryn C. Lee, Thomas A. Fleisher, Mark Raffeld, Elaine S. Jaffe, Maryalice Stetler-Stevenson, Stefania Pittaluga, Donn Stewart, Deirdre O'Mahony, John E. Janik, Kamal Sharma
Kaplan-Meier analysis of the survival for patients with ATL who responded to alemtuzumab therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8747d5d14eeaed03679515d841c40821
https://doi.org/10.1158/1078-0432.22467129
https://doi.org/10.1158/1078-0432.22467129
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8503f7c52a990afce6ce287288e5ed31
https://doi.org/10.1158/1078-0432.22440441.v1
https://doi.org/10.1158/1078-0432.22440441.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Purpose: We report an increased incidence of EBV-induced B-cell lymphoproliferative disease (LPD) in patients treated with siplizumab, an anti-CD2 antibody. The development of EBV-LPD has been associated with the use of immunosuppressive agents used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac91bb7565e1e40c0a53634257bdd81
https://doi.org/10.1158/1078-0432.c.6517770.v1
https://doi.org/10.1158/1078-0432.c.6517770.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4eabde20104a650691e9673ca704c1
https://doi.org/10.1158/1078-0432.22440444.v1
https://doi.org/10.1158/1078-0432.22440444.v1
Autor:
John C. Morris, Thomas A. Waldmann, Seth M. Steinberg, Cathryn C. Lee, Thomas A. Fleisher, Mark Raffeld, Elaine S. Jaffe, Maryalice Stetler-Stevenson, Stefania Pittaluga, Donn Stewart, Deirdre O'Mahony, John E. Janik, Kamal Sharma
Purpose: Therapeutic regimens for adult T-cell leukemia/lymphoma (ATL) are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::000826a48f76acbc8531f375d33bf8c1
https://doi.org/10.1158/1078-0432.c.6526545
https://doi.org/10.1158/1078-0432.c.6526545